A non-coding cancer mutation disrupting an HNF4α binding motif affects an enhancer regulating genes associated to the progression of liver cancer

Authors

  • M. Cavalli Uppsala University
  • K. Diamanti Uppsala University
  • G. Pan Uppsala University
  • M.J. Dabrowski Uppsala University
  • J. Komorowski nstitute of Computer Science, Polish Academy of Sciences, 01-248 Warszawa, Poland
  • C. Wadelius Uppsala University

DOI:

https://doi.org/10.32471/exp-oncology.2312-8852.vol-43-no-1.15925

Keywords:

gene regulation, liver cancer, motif-breaking mutations

Abstract

Background: Somatic mutations in coding regions of the genome may result in non-functional proteins that can lead to cancer or other diseases, however cancer mutations in the non-coding regions have rarely been studied and the interpretation of their effects is difficult. Non-coding mutations might act by breaking or creating transcription factor binding motifs in promoters, enhancers or silencers resulting in altered expression of target gene(s). A high number of mutations have been reported in coding and non-coding regions in cells of liver cancer. Hepatocyte nuclear factor 4α is a transcription factor that regulates the expression of several genes in liver cells, while the motifs it binds are frequently mutated in promoters and enhancers in liver cancer. Aim: The aim of the study is to evaluate the genetic effects of a non-coding somatic mutation frequently observed in liver cancer. Materials and Methods: We evaluated experimentally the effects of a somatic mutation frequently reported in liver cancer as a motif-breaker for the binding of hepatocyte nuclear factor 4α. The effects of the mutation on protein binding and enhancer activity were studied in HepG2 cells via electrophoresis mobility shift assay and dual luciferase reporter assays. We also studied genome-wide promoter-enhancer interactions performing targeted chromosome conformation capture in liver tissue to identify putative target genes whose expression could be altered by the mutation. Results: We found that the mutation leads to reduced protein binding and a decrease in enhancer activity. The enhancer harboring the mutation interacts with the promoters of ANAPC13, MAP6D1 and MUC13, which have been implicated in liver cancer. Conclusions: The study highlights the importance of non-coding somatic mutations, vastly understudied, but likely to contribute to cancer development and progression.

References

Dunham I, Kundaje A, Aldred SF, et al. An integrated encyclopedia of DNA elements in the human genome. Nature 2012; 489: 57–74.

Kundaje A, Meuleman W, Ernst J, et al. Integrative analysis of 111 reference human epigenomes. Nature 2015; 518: 317–30.

Rheinbay E, Nielsen MM, Abascal F, et al. Analyses of non-coding somatic drivers in 2,658 cancer whole genomes. Nature 2020; 578: 102–11.

Umer HM, Cavalli M, Dabrowski MJ, et al. A significant regulatory mutation burden at a high-affinity position of the CTCF motif in gastrointestinal cancers. Hum Mutat 2016; 37: 904–13.

Lieberman-Aiden E, van Berkum NL, Williams L, et al. Comprehensive mapping of long-range interactions reveals folding principles of the human genome. Science 2009; 326: 289–93.

Sahlén P, Abdullayev I, Ramsköld D, et al. Genome-wide mapping of promoter-anchored interactions with close to single-enhancer resolution. Genome Biol 2015; 16: 156.

Jäger R, Migliorini G, Henrion M, et al. Capture Hi-C identifies the chromatin interactome of colorectal cancer risk loci. Nat Commun 2015; 6: 6178.

Dryden NH, Broome LR, Dudbridge F, et al. Unbiased analysis of potential targets of breast cancer susceptibility loci by Capture Hi-C. Genome Res 2014; 24: 1854–68.

Weinhold N, Jacobsen A, Schultz N, et al. Genome-wide analysis of noncoding regulatory mutations in cancer. Nat Genet 2014; 46: 1160–5.

Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med 2017; 9: 34.

Zhang Y, Werling U, Edelmann W. SLiCE: a novel bacterial cell extract-based DNA cloning method. Nucleic Acids Res 2012; 40: e55.

Cavalli M, Diamanti K, Pan G, et al. A Multi-Omics approach to liver diseases: integration of single nuclei transcriptomics with proteomics and HiCap bulk data in human liver. OMICS 2020; 24: 180–94.

Fang B, Mane-Padros D, Bolotin E, et al. Identification of a binding motif specific to HNF4 by comparative analysis of multiple nuclear receptors. Nucleic Acids Res 2012; 40: 5343–56.

Lu P, Rha GB, Melikishvili M, et al. Structural basis of natural promoter recognition by a unique nuclear receptor, HNF4alpha. Diabetes gene product. J Biol Chem 2008; 283: 33685–97.

Rastinejad F, Wagner T, Zhao Q, et al. Structure of the RXR-RAR DNA-binding complex on the retinoic acid response element DR1. EMBO J 2000; 19: 1045–54.

Chandra V, Huang P, Potluri N, et al. Multidomain integration in the structure of the HNF-4α nuclear receptor complex. Nature 2013; 495: 394–8.

Taniguchi H, Fujimoto A, Kono H, et al. Loss-of-function mutations in Zn-finger DNA-binding domain of HNF4A cause aberrant transcriptional regulation in liver cancer. Oncotarget 2018; 9: 26144–56.

Uhlen M, Zhang C, Lee S, et al. A pathology atlas of the human cancer transcriptome. Science 2017; 357: eaan2507.

Wang D, Xin L, Lin J-H, et al. Identifying miRNA-mRNA regulation network of chronic pancreatitis based on the significant functional expression. Medicine 2017; 96: 21.

Ahmad W, Ijaz B, Hassan S. Gene expression profiling of HCV genotype 3a initial liver fibrosis and cirrhosis patients using microarray. J Transl Med 2012; 10: 41.

Ijaz B, Ahmad W, Das T, et al. HCV infection causes cirrhosis in human by step-wise regulation of host genes involved in cellular functioning and defense during fibrosis: Identification of bio-markers. Genes Dis 2019; 6: 304–17.

Gupta BK, Maher DM, Ebeling MC, et al. Increased expression and aberrant localization of mucin 13 in metastatic colon cancer. J Histochem Cytochem 2012; 60: 822–31.

Dai Y, Liu L, Zeng T, et al. Overexpression of MUC13, a poor prognostic predictor, promotes cell growth by activating wnt signaling in hepatocellular carcinoma. Am J Pathol 2018; 188: 378–91.

Tiemin P, Fanzheng M, Peng X, et al. MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR/PI3K/AKT pathways. J Hepatol 2020; 72: 761–73.

Downloads

Published

26.05.2023

How to Cite

Cavalli, M., Diamanti, K., Pan, G., Dabrowski, M., Komorowski, J., & Wadelius, C. (2023). A non-coding cancer mutation disrupting an HNF4α binding motif affects an enhancer regulating genes associated to the progression of liver cancer. Experimental Oncology, 43(1), 2–6. https://doi.org/10.32471/exp-oncology.2312-8852.vol-43-no-1.15925

Issue

Section

Original contributions